The OPHT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OPHT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The OPHT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View OPHT Detailed Price Forecast - CNN Money||View OPHT Detailed Summary - Google Finance|
|View OPHT Detailed Summary - Yahoo! Finance||View OPHT Stock Research & Analysis - Zacks.com|
|View OPHT Trends & Analysis - Trade-Ideas||View OPHT Major Holders - Barrons|
|View OPHT Call Transcripts - NASDAQ||View OPHT Breaking News & Analysis - Seeking Alpha|
|View OPHT Annual Report - CompanySpotlight.com||View OPHT OTC Short Report - OTCShortReport.com|
|View OPHT Fundamentals - TradeKing||View OPHT SEC Filings - Bar Chart|
|View Historical Prices for OPHT - The WSJ||View Performance/Total Return for OPHT - Morningstar|
|View the Analyst Estimates for OPHT - MarketWatch||View the Earnings History for OPHT - CNBC|
|View the OPHT Earnings - StockMarketWatch||View OPHT Buy or Sell Recommendations - MacroAxis|
|View the OPHT Bullish Patterns - American Bulls||View OPHT Short Pain Metrics - ShortPainBot.com|
|View OPHT Stock Mentions - StockTwits||View OPHT Stock Mentions - PennyStockTweets|
|View OPHT Stock Mentions - Twitter||View OPHT Investment Forum News - Investor Hub|
|View OPHT Stock Mentions - Yahoo! Message Board||View OPHT Stock Mentions - Seeking Alpha|
|View Insider Transactions for OPHT - SECform4.com||View Insider Transactions for OPHT - Insider Cow|
|View OPHT Major Holdings Summary - CNBC||View Insider Disclosure for OPHT - OTC Markets|
|View Insider Transactions for OPHT - Yahoo! Finance||View Institutional Holdings for OPHT - NASDAQ|
|View OPHT Stock Insight & Charts - FinViz.com||View OPHT Investment Charts - StockCharts.com|
|View OPHT Stock Overview & Charts - BarChart||View OPHT User Generated Charts - Trading View|
electroCore, Inc. Announces Additions to Board of Directors in Connection with Recently Completed Initial Public Offering
Posted on Tuesday July 10, 2018
BASKING RIDGE, N.J., July 10, 2018-- electroCore, Inc., a commercial-stage bioelectronic medicine company, today announced the appointment of Carrie S. Cox as Chairman of its Board of Directors, and Michael ...
Ophthotech (OPHT) Soars: Stock Adds 10.4% in Session
Posted on Friday June 08, 2018
Ophthotech (OPHT) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Ophthotech Corporation
Posted on Friday June 08, 2018
NEW YORK, NY / ACCESSWIRE / June 8, 2018 / While Proteostasis Therapeutics announced positive results from an ongoing 14-day dosing study of PTI-801, an analyst at RBC Capital Markets didn't seem impressed and downgraded the company this week as well as lowered his price target on shares. Ophthotech Corporation saw a different story yesterday, gaining over 10% after announcing that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania. The results had shown statistically significant improvement in sweat chloride, body mass index, and weight and blood glucose.
Ophthotech Enters into Gene Therapy Agreements with the University of Florida and the University of Pennsylvania
Posted on Thursday June 07, 2018
Ophthotech Corporation (OPHT) announced today that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania (Penn) to develop and commercialize a novel adeno-associated virus (AAV) gene therapy product for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), an orphan monogenic disease that is characterized by progressive and severe loss of vision leading to blindness. Preclinical anatomical and functional proof-of-concept studies have demonstrated promising results in a canine disease model. In addition to the exclusive license agreement, Ophthotech and Penn have also entered into a master sponsored research agreement, facilitated by the Penn Center for Innovation (PCI), pursuant to which Ophthotech and Penn plan to conduct preclinical and natural history studies.